Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Accumulated Expenses (2016 - 2025)

Sangamo Therapeutics has reported Accumulated Expenses over the past 16 years, most recently at $17.7 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $17.7 million for Q4 2025, up 116.24% from a year ago — trailing twelve months through Dec 2025 was $17.7 million (up 116.24% YoY), and the annual figure for FY2025 was $17.7 million, up 116.24%.
  • Accumulated Expenses for Q4 2025 was $17.7 million at Sangamo Therapeutics, up from $9.9 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for SGMO hit a ceiling of $21.5 million in Q4 2022 and a floor of $5.7 million in Q2 2024.
  • Median Accumulated Expenses over the past 5 years was $13.9 million (2022), compared with a mean of $13.6 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 70.18% in 2024 and later skyrocketed 146.47% in 2025.
  • Sangamo Therapeutics' Accumulated Expenses stood at $20.8 million in 2021, then grew by 3.2% to $21.5 million in 2022, then tumbled by 58.53% to $8.9 million in 2023, then dropped by 8.11% to $8.2 million in 2024, then skyrocketed by 116.24% to $17.7 million in 2025.
  • The last three reported values for Accumulated Expenses were $17.7 million (Q4 2025), $9.9 million (Q3 2025), and $13.9 million (Q2 2025) per Business Quant data.